首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >A SMALL BISPECIFIC ANTIBODY CONSTRUCT EXPRESSED AS A FUNCTIONAL SINGLE-CHAIN MOLECULE WITH HIGH TUMOR CELL CYTOTOXICITY
【24h】

A SMALL BISPECIFIC ANTIBODY CONSTRUCT EXPRESSED AS A FUNCTIONAL SINGLE-CHAIN MOLECULE WITH HIGH TUMOR CELL CYTOTOXICITY

机译:具有高肿瘤细胞毒性的功能性单链分子表达的小双特异性抗体构建体

获取原文
获取原文并翻译 | 示例
       

摘要

Construction of a bispecific single-chain antibody derivative is described that consists of two different single-chain Fv fragments joined through a Gly-Ser linker. One specificity of the two Fv fragments is directed against the CD3 antigen of human T cells and the other is directed against the epithelial 17-1A antigen; the latter had been found in a clinical trial to be a suitable target for antibody therapy of minimal residual colorectal cancer. The construct could be expressed in CHO cells as a fully functional protein, while its periplasmic expression in Escherichia coil resulted in a nonfunctional protein only. The antigen-binding properties of the bispecific single-chain antibody are indistinguishable from those of the corresponding univalent single-chain Fv fragments. By redirecting human peripheral T lymphocytes against 17-1A-positive tumor cells, the bispecific antibody proved to be highly cytotoxic at nanomolar concentrations as demonstrated by Cr-51 release assay on various cell lines. The described bispecific construct has a molecular mass of 60 kDa and can be easily purified by its C-terminal histidine tail on a Ni-NTA chromatography column. As bispecific antibodies have already been shown to be effective in vivo in experimental tumor systems as well as in phase-one clinical trials, the small CD3/17-1A-bispecific antibody may be more efficacious than intact antibodies against minimal residual cancer cells. [References: 40]
机译:描述了双特异性单链抗体衍生物的构建,其由通过Gly-Ser接头连接的两个不同的单链Fv片段组成。这两个Fv片段的一种特异性针对人T细胞的CD3抗原,另一种特异性针对上皮17-1A抗原。后者已在临床试验中被发现是最小残留结肠直肠癌抗体治疗的合适靶标。该构建体可以作为全功能蛋白在CHO细胞中表达,而其在大肠杆菌中的周质表达仅导致无功能蛋白。双特异性单链抗体的抗原结合特性与相应的单价单链Fv片段的抗原结合特性没有区别。通过针对17-1A阳性肿瘤细胞重定向人外周血T淋巴细胞,双特异性抗体被证明在纳摩尔浓度下具有很高的细胞毒性,如在各种细胞系上通过Cr-51释放测定所证明的那样。所描述的双特异性构建体的分子量为60 kDa,可以通过Ni-NTA色谱柱上的C端组氨酸尾部轻松纯化。由于双特异性抗体在实验性肿瘤系统以及一期临床试验中已显示出体内有效,因此针对最小残留癌细胞的小CD3 / 17-1A双特异性抗体可能比完整抗体更有效。 [参考:40]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号